

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application: /
Rapoport /
U.S. Serial No. 08/482,402 /
CPA Filed: 06/07/95 /
For: **DISEASE ASSOCIATED HUMAN** /
AUTOANTIBODIES SPECIFIC FOR /
HUMAN THYROID PEROXIDASE /

Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT


Sir:

In accordance with 37 C.F.R. 1.56 and 1.97, Applicants wish to call the attention of the Examiner to the references that are listed on the attached PTO form 1449, copies of which are submitted herewith.

Applicant respectfully requests that the cited references be listed on the face of any patent issuing from this application.

These citations do not constitute an admission that the references are relevant or material to the claims, but rather only constitute the closest art of which Applicants are presently aware.

Respectfully Submitted



Donald E. Stout
Attorney for Applicants
Registration No. 34,493

November 9, 2000
4 Venture, Suite 300
Irvine, CA 92618
949-450-1750

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal service as first class mail in an envelope addressed to:
Commissioner for Patents
Washington, D.C. 20231

Signature: 
Dawn Zuniga

Date: 11/9/00

Form PTO-1449

Docket Number (Optional) 102105-CT-13

Application Number 08/482,402

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

Applicant Rapoport

Filing Date 06/07/95

Group Art Unit 1642

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		“ENGINEERING THE HUMAN THYROTROPIN RECEPTOR ECTODOMAIN FROM A NON-SECRETED FORM TO A SECRETED, HIGHLY IMMUNOREACTIVE GLYCOPROTEIN THAT NEUTRALIZES AUTOANTIBODIES IN GRAVES’ PATIENTS’ SERA” by Chazenbalk et al.; <i>The Journal of Biological Chemistry</i> , Vol. 272, No. 30, Issue of July 25, pp. 18959-18965, 1997

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 809; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to the applicant.